Structure Therapeutics Inc.
A biopharmaceutical company developing oral pills for chronic conditions, most notably a once-daily GLP-1 drug called aleniglipron aimed at obesity and type 2 diabetes. It was founded in 2016 by structural biologist Raymond Stevens alongside the drug-design firm Schrödinger, and originally went by the name ShouTi before rebranding to highlight its structure-based approach. Its stock ticker, GPCR, nods to the family of cell receptors—G protein-coupled receptors—that its medicines target.
Sponsored ADS, each representing three ordinary shares
Granted 313.9K
Granted 840.2K
Granted 291.5K
Granted 311.1K
Granted 184.6K
Granted 166.0K
Granted 120.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| FIL LtdSee Remark 1 · 9 transactions | — | 6.29Mas of Feb 2023 | — | — | — |
| Farid RamyDirector · 1 transaction | — | 3.26Mas of Feb 2023 | — | — | — |
| Yoon JunCHIEF FINANCIAL OFFICER · 6 transactions | — | 2.96M | 313.9K | — | — |
| Stevens Raymond CCHIEF EXECUTIVE OFFICER, Director · 9 transactions | — | 2.96M | 840.2K | — | — |
| Biotechnology Value Fund II LP +9 co-filersSee explanation of responses, 10% owner · 3 transactions | — | 2.80Mas of May 2023 | — | — | — |
| Coll Crespo BlasCHIEF MEDICAL OFFICER · 8 transactions | — | 280.9K | 291.5K | — | — |
| FMR LLCSee Remark 1 · 9 transactions | — | 261.8K | — | — | — |
| Lin XichenCHIEF SCIENTIFIC OFFICER · 10 transactions | — | 229.0K | 311.1K | — | — |
| Lang MatthewCOO & GC · 1 transaction | — | 184.6K | 184.6K | — | — |
| Hall AshleyChief Development Officer · 5 transactions | — | 155.2K | 166.0K | — | — |
| Ma YingliCHIEF TECHNOLOGY OFFICER · 6 transactions | — | 139.9K | 120.8K | — | — |
| Welch Daniel GDirector · 1 transaction | — | 123.5Kas of Feb 2023 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.